Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NPY2R | P49146 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4608914 | 0.85 | SLC6A3 (0.47) | NPY1RHTTNPY2R | |
| SCHEMBL4653088 | 0.83 | NPY1R (0.47) | NPY1RHTTNPY2RALDH1A1POLB | |
| SCHEMBL4653085 | 0.83 | NPY1R (0.47) | NPY1RHTTNPY2RALDH1A1POLB | |
| SCHEMBL4653089 | 0.83 | NPY1R (0.47) | NPY1RHTTNPY2RALDH1A1POLB | |
| SCHEMBL14538699 | 0.82 | LTA4H (0.49) | HTT | |
| SCHEMBL4651854 | 0.81 | NPY1R (0.41) | NPY1RHTTNPY2RALDH1A1TSHR | |
| SCHEMBL4609111 | 0.80 | HRH3 (0.48) | — | |
| SCHEMBL4624618 | 0.80 | HRH3 (0.48) | — | |
| SCHEMBL4607992 | 0.80 | HRH3 (0.48) | — | |
| SCHEMBL14538713 | 0.80 | HRH3 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294854-A1 | SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | US | claimed |
| US-8796470-B2 | Substituted octahydrocyclopenta[c]pyrroles as calcium channel modulators | ABBVIE INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20110294854-A1 | SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294854-A1 | SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS | ORAI1, CACNA1E, RYR1 | NPY1R 213/4885HTT 1436/4885NPY2R 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.